Market Overview

SentreHEART Announces Participation at The American College of Cardiology's 67th Annual Scientific Session & Expo

Share:

SentreHEART, Inc., the manufacturer of the LARIAT® Suture Delivery
Device (LARIAT) will be participating in the American College of
Cardiology (ACC) 2018 meeting being held in Orlando, Florida, March
10-12, 2018.

This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20180308006483/en/

The meeting's agenda includes several sessions dedicated to exploring
device-based options for Left Atrial Appendage (LAA) closure in patients
diagnosed with atrial fibrillation (AFib). Physician thought leaders in
this field will be relating their experience and presenting data, which
will include transpericardial LAA closure with the LARIAT in multiple
AFib patient populations.

Studies have demonstrated the LARIAT not only closes the LAA mechanically1
but may also isolate electrical activity within the LAA2.
With a commitment to clinical evidence development, SentreHEART is
presently sponsoring the FDA-approved, prospective, multi-center,
randomized controlled Trial known as the aMAZE Trial. The trial,
in its unique superiority design, targets the most challenging AFib
population of persistent and long-persistent AFib patients, is intended
to demonstrate a LARIAT procedure for LAA closure, plus a subsequent PVI
ablation will lead to a reduced incidence of recurrent AFib compared to
PVI alone; with a high safety profile.

Having a non-implant option that may both electrically and mechanically
isolate the LAA is a potentially important addition to the treatment
armamentarium for clinicians treating patients with persistent or
longstanding persistent Afib. The LARIAT has the potential to eliminate
the LAA as a source of AFib and nidus for thrombus.

Attendees of ACC.18 who are interested in learning more about the aMAZE
Trial and LARIAT procedure may visit the SentreHEART Booth #2757
in the Exhibit Hall during the meeting.

ABOUT THE LARIAT SUTURE DELIVERY DEVICE

The LARIAT Suture Delivery Device is indicated for suture placement and
knot tying in surgical procedures where soft tissues are being
approximated and/or ligated with a pre-tied polyester suture.
SentreHEART received FDA 510(k) clearances for the LARIAT in 2006, 2009
and 2014. The LARIAT device is also CE Marked in Europe.

ABOUT SENTREHEART

SentreHEART is a privately owned medical device company based in Redwood
City, CA. Founded in 2005, SentreHEART has developed technology for
remote delivery of suture for closure of anatomic structures.

aMAZE is an FDA-approved Trial – U.S. FDA IDE# G150107

Clinicaltrials.gov Identifier: NCT02513797

For more information, please visit www.amazetrial.com
and follow us on Twitter @amazetrial.

1 Bartus K, et al. Percutaneous Left Atrial Appendage Suture Ligation
Using the LARIAT Device in Patients with Atrial Fibrillation. J Am Coll
Cardiol 2013 Jul 9;62(2):108-18

2 Han FT, et al. The Effects of LAA Ligation on Electrical Activity.
Heart Rhythm. 2014 May; 11(5):864-70

View Comments and Join the Discussion!